October 8th 2024
The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.
Updated Findings Confirm Nivolumab OS Benefit in SCCHN
April 18th 2018Patients with metastatic or recurrent squamous cell carcinoma of the head and neck experienced a 32% reduction in the risk of death compared with investigator's choice of therapy, according to updated findings with a minimum of 2 years of follow-up from the phase III CheckMate-141 study.
Read More
FDA Places Hold on Axalimogene Filolisbac Plus Durvalumab Trial in Cervical, Head and Neck Cancer
March 14th 2018The FDA has placed a clinical hold on a phase I/II study of axalimogene filolisbac and durvalumab, according to an announcement by Advaxis, the manufacturer of axalimogene filolisbac, in a quarterly earnings report.The study is evaluating the combination in patients with advanced, recurrent or refractory HPV-associated cervical cancer and HPV-associated head and neck squamous cell carcinoma.
Read More
Jean Kozempel to Receive 2017 Oncology Section President's Award
February 27th 2018The American Physical Therapy Association has selected Jean Kozempel, PT, DPT, MS, as the recipient of the 2017 Oncology Section President’s Award. This award honors physical therapists who are proving themselves to be pioneers in the oncology field.
Read More
Activity Seen With Tipifarnib in HRAS-Mutant HNSCC in Proof-of-Concept Study
December 27th 2017Tipifarnib demonstrated encouraging antitumor activity among patients with <em>HRAS</em>-mutant head and neck squamous cell carcinoma (HNSCC), according to preliminary results of an ongoing phase II proof-of-concept trial (NCT02383927).
Read More
Exciting Response Rates Seen in Updates Findings of bb2121 in Multiple Myeloma
December 13th 2017Chimeric antigen receptor T-cell therapy with bb2121 demonstrated an objective response rate of 94% in patients with relapsed/refractory multiple myeloma, according to findings from a dose-escalation study. The senior study author, James N. Kochenderfer, MD, presented updated findings from the study during the 2017 ASH Annual Meeting, and commented that 89% of patients had a very good partial response or better, and 56% of patients had a complete remission. <br />
Read More
Jennifer Eads, MD, assistant professor of medicine, senior clinical instructor of medicine, University Hospitals Cleveland Medical Center, discusses the difficulties in diagnosing G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs), and the varying treatment approaches for these subsets of patients.
Watch
The Current Role of Checkpoint Inhibitors in Head and Neck Cancer
October 10th 2017Everett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, Chair, Department of Medicine, discusses the current role of checkpoint inhibitors for the treatment of head and neck cancer during the ESMO 2017 Congress.
Watch